The price of AIM ImmunoTech Inc. (AMEX:AIM) shares last traded on Wall Street rose 26.02% to $0.41.
Based on available information, 3 analysts follow AIM ImmunoTech Inc. (AMEX:AIM). The consensus rating among analysts is ‘Buy’. AIM stock price is now -7.98% away from the 50-day moving average and -43.65% away from the 200-day moving average. The market capitalization of the company currently stands at $19.24M.
Among analysts, 0 rate the stock a hold while 3 rate it a buy.
In other news, Equels Thomas K, CEO & President bought 161,291 shares of the company’s stock on Jan 03. The stock was bought for $50,000 at an average price of $0.31. Upon completion of the transaction, the CEO & President now directly owns 543,995 shares in the company, valued at $0.22 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jan 03, COO, Secretary, Gen. Counsel Rodino Peter W III bought 80,646 shares of the business’s stock. A total of $25,000 was incurred on buying the stock at an average price of $0.31. This leaves the insider owning 143,839 shares of the company worth $58973.99. A total of 0.80% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in AIM stock. A new stake in AIM ImmunoTech Inc. shares was purchased by MILLENNIUM MANAGEMENT LLC during the first quarter worth $12,000. In total, there are 44 active investors with 12.30% ownership of the company’s stock.
A candlestick chart of AIM ImmunoTech Inc. (AMEX: AIM) showed a price of $0.3900 on Wednesday morning. During the past 12 months, AIM ImmunoTech Inc. has had a low of $0.29 and a high of $1.38. As of last week, the company has a debt-to-equity ratio of 0.00, a current ratio of 14.20, and a quick ratio of 14.20. The fifty day moving average price for AIM is $0.4444 and a two-hundred day moving average price translates $0.7249 for the stock.
The latest earnings results from AIM ImmunoTech Inc. (AMEX: AIM) was released for Jun, 2022. According to the Biotechnology Company, earnings per share came in at -$0.1, missing analysts’ expectations of -$0.07 by -0.03. This compares to -$0.08 EPS in the same period last year. The company reported revenue of $21000.0 for the quarter, compared to $33000.0 a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -36.36 percent. For the current quarter, analysts expect AIM to generate $150k in revenue.
AIM ImmunoTech Inc.(AIM) Company Profile
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company’s products include Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, prostate and pancreatic cancer, myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat genital warts, a sexually transmitted disease. It has agreements with UMN Pharma Inc.; Japanese National Institute of Infectious Diseases; Shionogi & Co., Ltd.; Polysciences Inc.; and University of Cagliari Dipartimento di Scienze della Vita e dell’Ambiente. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.